Details of the Drug

General Information of Drug (ID: DMS2M7O)

Drug Name

Deferiprone

Synonyms

Ferriprox (TN)

Indication

Disease Entry	ICD 11	Status	REF
Beta thalassemia	3A50.2	Approved	[1]
Iron overload disease	5C64.10	Approved	[1]
Thalassemia	3A50	Approved	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

139.15

Logarithm of the Partition Coefficient (xlogp)

0.5

Rotatable Bond Count (rotbonds)

0

Hydrogen Bond Donor Count (hbonddonor)

1

Hydrogen Bond Acceptor Count (hbondacc)

3

ADMET Property

Half-life: The concentration or amount of drug in body reduced by one-half in 1.9 hours [3]
Metabolism: The drug is metabolized via UGT1A6 to the 3-O-glucuronide metabolite []
Vd: The volume of distribution (Vd) of drug is 1 L/kg []

Chemical Identifiers

Formula: C7H9NO2
IUPAC Name: 3-hydroxy-1,2-dimethylpyridin-4-one
Canonical SMILES: CC1=C(C(=O)C=CN1C)O
InChI: InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3
InChIKey: TZXKOCQBRNJULO-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 2972
ChEBI ID: CHEBI:68554
CAS Number: 30652-11-0
DrugBank ID: DB08826
TTD ID: D0N0OU
INTEDE ID: DR1762
ACDINA ID: D00173

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Iron (Fe)	TTUDR0C	NOUNIPROTAC	Modulator	[4]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
UDP-glucuronosyltransferase 1A6 (UGT1A6)_{Main DME}	DESD26P	UD16_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Frataxin, mitochondrial (FXN)	OTE9U09A	FRDA_HUMAN	Gene/Protein Processing	[6]
Serotransferrin (TF)	OT41PEMS	TRFE_HUMAN	Gene/Protein Processing	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Deferiprone (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Deferiprone caused by PF-06463922 mediated induction of UGT.	Lung cancer [2C25]	[8]
PRX-321	DM7YWVT	Moderate	Decreased metabolism of Deferiprone caused by PRX-321 mediated inhibition of UGT.	Solid tumour/cancer [2A00-2F9Z]	[9]
-----------

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Magnesium stearate	E00208	11177	lubricant
Polyethylene glycol 3350	E00652	Not Available	Coating agent; Diluent; Ointment base; Plasticizing agent; Solvent; Suppository base; lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
--------------------

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Deferiprone 500 mg tablet	500 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	Deferiprone FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7456).
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
5	Deferiprone glucuronidation by human tissues and recombinant UDP glucuronosyltransferase 1A6: an in vitro investigation of genetic and splice variants. Drug Metab Dispos. 2009 Feb;37(2):322-9.
6	Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia. PLoS One. 2013;8(2):e55940.
7	Antiproliferative effect of deferiprone on the Hep G2 cell line. Biochem Pharmacol. 1998 Aug 15;56(4):431-7. doi: 10.1016/s0006-2952(98)00071-9.
8	Cerner Multum, Inc. "Australian Product Information.".
9	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.